Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04676061 · ClinicalTrials.gov registry record · Phase 4
Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™
A Phase 4 study, sponsored by Baylor Research Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT04676061: Clinical Trial Phase 4 study, sponsored by Baylor Research Institute.
NCT04676061 is a Phase 4 study that was terminated before completion, run by Baylor Research Institute. The registered enrollment target is 51 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04676061, a Phase 4 study, was terminated before completion, sponsored by Baylor Research Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
Effects of norethindrone acetate (NTA) in patients with Nexplanon.
Primary Outcome
To evaluate days of bleeding and spotting within 90-day intervals by quantifying a self-perception of amount of bleeding on a scale of 0 to 4 and associated symptoms on a scale of 0 to 10 using the Daily Dairy of Symptoms
Interventions
- DRUG Placebo
- DRUG Norethindrone acetate (NTA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-02-11 |
| Est. Completion | 2023-03-10 |
| Phase | Phase 4 |
Why NCT04676061 stopped before completion
NCT04676061 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04676061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04676061 about?
NCT04676061 is a clinical study titled "Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™". Effects of norethindrone acetate (NTA) in patients with Nexplanon.
What is the current status of trial NCT04676061?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2021-02-11. Estimated completion is 2023-03-10.
What interventions are being tested in trial NCT04676061?
The interventions under investigation include: Placebo (DRUG), Norethindrone acetate (NTA) (DRUG).
Who is sponsoring clinical trial NCT04676061?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04676061's enrollment target sits among peer trials
51 1249th of 2000 higher than 746 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI